A Dose‐Aware Model for Revealing Dose‐Risk Relationship of Drug–Drug Interaction

Drug-drug interaction (DDI) is a common cause of adverse drug events (ADEs). Despite real-world data-based studies have developed knowledge on DDI, the precise relationships between doses of two-drug combinations exposure and the risks of ADEs remain largely unknown. The estimation of the dose-risk relationship (DRR) under commonly used regression models could be subject to model misspecification or overspecification. We developed a dose-aware model (DAM) for revealing DRR. DAM could improve the DRR estimation by identifying the optimal model from a large number of meaningful models of doses of two-drug combinations exposure and risks of ADE. We compared DAM with commonly used models (e.g., exposed-versus-unexposed model, dose-response model, and saturated model), in which DAM had higher performance metrics on model fitting in real-world data analyses and DRR estimation in a simulation study. In conclusion, DAM is a powerful tool for estimating DRR for potential adverse two-drug combinations, which could be used to mitigate DDI-induced harm.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2025-09-18
DOI
https://doi.org/10.1002/psp4.70114
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Dose‐Aware Model for Revealing Dose‐Risk Relationship of Drug–Drug Interaction

Yuedi Yang, Michael T. Eadon, Hongmei Nan, Anna Sun et al.
CPT Pharmacometrics & Systems Pharmacology
Pharmacovigilance and Adverse Drug Reactions
article

A Dose‐Aware Model for Revealing Dose‐Risk Relationship of Drug–Drug Interaction

Yuedi Yang, Michael T. Eadon, Hongmei Nan, Anna Sun, Jing Xu, Pengyue Zhang, Mu Shan, Yi Shi, Jing Su
article en

Abstract

Drug-drug interaction (DDI) is a common cause of adverse drug events (ADEs). Despite real-world data-based studies have developed knowledge on DDI, the precise relationships between doses of two-drug combinations exposure and the risks of ADEs remain largely unknown. The estimation of the dose-risk relationship (DRR) under commonly used regression models could be subject to model misspecification or overspecification. We developed a dose-aware model (DAM) for revealing DRR. DAM could improve the DRR estimation by identifying the optimal model from a large number of meaningful models of doses of two-drug combinations exposure and risks of ADE. We compared DAM with commonly used models (e.g., exposed-versus-unexposed model, dose-response model, and saturated model), in which DAM had higher performance metrics on model fitting in real-world data analyses and DRR estimation in a simulation study. In conclusion, DAM is a powerful tool for estimating DRR for potential adverse two-drug combinations, which could be used to mitigate DDI-induced harm.

CPT Pharmacometrics & Systems PharmacologyVol. 14(12)
Eli Lilly (United States) (US), Richard M. Fairbanks Foundation (US), Indiana University Indianapolis (US), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US)
National Institutes of Health
Openalex Percentile: Top 76%
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Dose‐Aware Model for Revealing Dose‐Risk Relationship of Drug–Drug Interaction — Yuedi Yang, Michael T. Eadon, et al. · CPT Pharmacometrics & Systems Pharmacology (2025) | TGRS Research Map | TGRS